Total Funding
73
58
Total FundingSeries A raised
Growth Score
-7 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
49442
Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.
- Ellen Donnelly: Chief Executive OfficerPast Role: Abliva AB, Chief Executive Officer
About the Company
Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.
